European Journal of Cancer
Volume 38 , Pages S25-S31 , December 2002

ZD0473 combined with other chemotherapeutic agents for the treatment of solid malignancies

  • J-Y Douillard

      Affiliations

    • CRLCC Nantes-Atlantique, Nantes-Saint Herblain, France
    • Tel.: +33 2 40 67 99 78; Fax: +33 2 40 67 97 76
    • ,
  • J Schiller

      Affiliations

    • University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA

References 

  1. du Bois A. Treatment of advanced ovarian cancer. Eur J Cancer. 2001;37(Suppl. 9):S1–S7
  2. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology. 2001;61(Suppl. 1):3–13
  3. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer. 1998;34:1535–1542
  4. Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol. 1998;9:13–21
  5. Holford J, Raynaud F, Murrer BA, Grimaldi K, Hartley JA, Abrams M, et al.  Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473). Anticancer Drug Des. 1998;13:1–18
  6. Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer. 1998;77:366–373
  7. Gore M, Atkinson RJ, Dirix L, Rischin D, Beale P, Harnet P, et al.  ZD0473 phase II monotherapy trial in second-line ovarian cancer. Eur J Cancer. 2001;37:S261; (Abstr 967)
  8. Schiller J, Bonomi P, Modiano M, Cornett P, Kohler M. Activity of ZD0473 in small-cell lung cancer: an update in patients relapsing after one prior chemotherapy regimen. Eur J Cancer. 2001;37:S62; (Abstr 219)
  9. Hoctin-Boes G, Cosaert J, Koehler M, Smith M. Safety profile of ZD0473 in Phase II trials of patients with advanced cancers. In: Proc Am Soc Clin Oncol. 344:2001;p. 1372; (abstr)
  10. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, et al.  Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998;16:2459–2465
  11. Colleoni M, Boni L, Vicario G, Pancheri F, Sgarbossa G, Nelli P, et al.  A dose-escalating study of carboplatin combined with vinorelbine in non-small-cell lung cancer. Oncology. 1996;53:364–368
  12. Santomaggio C, Tucci E, Rinaldini M, Algeri R, Righi R, Pepi F, et al.  Carboplatin and vinorelbine in the treatment of advanced non-small-cell lung cancer: a multicenter phase II study. Am J Clin Oncol. 1998;21:67–71
  13. Gridelli C, Perrone F, Ianniello GP, Brancaccio L, Iaffaioli RV, Curcio C, et al.  Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologio Centro-Su-Isole. J Clin Oncol. 1998;16:1414–1419
  14. Berthaud P, Le Chevalier T, Ruffie P, Baldeyrou P, Arriagada R, Besson F, et al.  Phase I–II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer. 1992;28A:1863–1865
  15. Jacoulet P, Breton JL, Westeel V, Mercier M, Garnier G, Depierre A. Phase I study of vinorelbine and carboplatin in advanced non-small cell lung cancer. Lung Cancer. 1995;12:247–257
  16. ten Bokkel HW, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al.  Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183–2193
  17. Dunton CJ, Neufeld J, Carlson JA. Secondary response of ovarian tumors to topotecan treatment. Gynecol Oncol. 1998;69:258–259
  18. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al.  Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658–667
  19. Bookman MA. Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group. Int J Gynecol Cancer. 2001;11(Suppl. 1):42–51
  20. Rogers PM, Boxall F, Allott CP, Stephens T, Kelland LR. In vitro combination studies with the sterically hindered platinum drug, ZD0473, in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Clin Cancer Res. 2000;6:352; (abstr)
  21. Gatzemeier U, Twelves C, Anthoney DA, Pentheroudakis G, Groth G, Cosaert J. A phase I dose-escalation study of ZD0473 in combined with paclitaxel in refractory solid malignancies. Eur J Cancer. 2001;37:74–75 (abstr) Gatzemeier U, Twelves C, Anthoney DA, Pentheroudakis G, Groth G, Cosaert J. A phase I dose-escalation study of ZD0473 in combined with paclitaxel in refractory solid malignancies. Eur J Cancer. 2001;37:264; (abstr)
  22. O'Dwyer PJ, Stevenson JP, Redlinger M, et al.  Phase I trial of the novel platinum analogue ZD0473 in combination with gemcitabine (GEM) for patients with advanced cancers. In: Proc Am Soc Clin Oncol. 20:2001;p. 1354; (abstr)
  23. Dizon DS, Maluf F, Aghajanian C, Daud D, Sabbatini P, Soignet S, et al.  Phase I study of ZD0473 and liposomal doxorubicin in advanced refractory solid tumour malignancies. Eur J Cancer. 2001;37:S77; (Abstr 273)
  24. Gelmon KA, Stewart D, Ayers D, Fry D, Douglas L, McIntosh LW, et al.  A Phase I study of ZD0473 and docetaxel given once every three weeks in patients with advanced refractory cancer. A National Cancer Institute of Canada Clinical Trials Group Study (NCIC CTG-IND 131). Eur J Cancer. 2002;37:S72; (Abstr 254)
  25. Douillard JY, Cosaert J, Barbot V. Phase I trial of ZD0473 in combination with vinorelbine for patients with advanced cancer. Eur J Cancer. 2001;37:S77; (Abstr 273)
  26. Crawford J, O'Rourke MA. Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor. Semin Oncol. 1994;21:73–78
  27. Masters G. Carboplatin and vinorelbine in advanced non-small cell lung cancer: a phase I/II study. Oncologist. 2001;6(Suppl. 1):12–15
  28. Verweij J, Lund B, Beijnen J, Planting A, Boer-Dennert M, Koier I, et al.  Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol. 1993;4:673–678
  29. Homesley HD, Hall DJ, Martin DA, Lewandowski GS, Vaccarello L, Nahhas WA, et al.  A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol. 2001;83:394–399
  30. Kakolyris S, Kouroussis C, Souglakos J, Mavroudis D, Agelaki S, Kalbakis K, et al.  A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors. Oncology. 2001;61:265–270
  31. Bolis G, Scarfone G, Sciatta C, Polverino GP, Rosa C, Guarnerio P, et al.  A phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol. 2001;83:477–480
  32. Bowman A, Rye T, Ross G, Wheatley A, Smyth JF. Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: a phase I/II study. J Clin Oncol. 2001;19:3255–3259
  33. Athale UH, Stewart C, Kuttesch JF, Moghrabi A, Meyer W, Pratt C, et al.  Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol. 2002;20:88–95
  34. Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol. 1994;12:2743–2750
  35. Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, et al.  Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol. 1996;14:3074–3084
  36. Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL, et al.  Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and Leukemia Group B study. J Clin Oncol. 1998;16:3302–3309
  37. Ghamande SA, Piver MS. Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: a Phase II pilot study. J Surg Oncol. 1992;72:162–166
  38. Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Tzy-Jyun Y, et al.  Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst. 1993;85:1499–1507

PII: S0959-8049(02)80020-X

European Journal of Cancer
Volume 38 , Pages S25-S31 , December 2002

Article Tools